Aug 12, 2020
Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing
Jun 10, 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
May 27, 2020
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
May 19, 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Mar 09, 2020
F2G Receives US FDA Orphan Drug Designation for Olorofim
Feb 03, 2020
Global Invasive Fungal Infection (IFI) Market Report 2020 - Surging Demand for Low-Cost Pipeline Products, Increase in Use of Broad-Spectrum Antibiotics
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Sep 24, 2019
Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
Sep 09, 2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
Jul 09, 2019
Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study
Mar 14, 2019
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Feb 07, 2019
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
Jan 30, 2019
TOLSURA (TM) (SUBA®-itraconazole) Antifungal Capsule Now Available in the United States
Jan 07, 2019
F2G Expands Investor Syndicate and Progresses Phase 2b Study for Novel Antifungal
Dec 11, 2018
Mayne Pharma receives FDA approval of Tolsura(TM) (SUBA®-itraconazole capsules) for the treatment of certain fungal infections
Nov 21, 2018
Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Nov 13, 2018
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update